INVO Fertility Inc. shares fell 14.78% to $2.02 on Wednesday after closing at $2.37 with a 191.73% increase on Tuesday, indicating market uncertainty regarding its future performance.
The company signed a definitive purchase agreement in December 2025 to acquire Family Beginnings, P.C., for $750,000, which includes $350,000 in cash and $400,000 in preferred stock, with the transaction expected to close by February 27, 2026. Despite reporting third-quarter 2025 revenue of $1,757,094, a 23% increase year-over-year, INVO faced a net loss of $2.6 million, highlighting financial challenges despite revenue growth.
With a market capitalization of $5.67 million, INVO's stock has declined 98.25% over the past 12 months, currently trading near its 52-week low, reflecting cautious market sentiment about its future price movements.
INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
